Transforming growth factor-β

Clinical Immunology and Immunopathology

Volumn 83, Issue 1, 1997, Pages 25-30

  Cox, David A ^a   Maurer, Thomas ^b  

^a CNS Research   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

CANCER CHEMOTHERAPY; CELL PROTECTION; CONFERENCE PAPER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; WOUND HEALING;

EID: 0031127541     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.4308     Document Type: Conference Paper

References (34)

1. 1. Roberts, A. B., and Sporn, M. B., The transforming growth factor-βs. In "Handbook of Experimental Pharmacology: Peptide Growth Factors and Their Receptors" (M. B. Sporn and A. B. Roberts, Eds.), pp. 419-472, Springer-Verlag, New York, 1990.
2. 2. Kingsley, D. M., The TGF-β superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8, 133-146, 1994.
3. 3. Mittl, P. R. E., Priestle, J. P., Cox, D. A., McMaster, G., Cerletti, N., and Grütter, M. G., The crystal structure of TGF-β3 and comparison to TGF-β2: Implications for receptor binding. Protein Sci. 5, 1261-1271, 1996.
4. 4. Massagué, J., TGFβ signaling: Receptors, transducers, and Mad proteins. Cell 85, 947-950, 1996.
5. 5. Roberts, A. B., Transforming growth factor-β: Activity and efficacy in animal models of wound healing. Wound Repair Regen. 3, 408-418, 1995.
6. 6. Cox, D. A., Transforming growth factor-beta 3. Cell Biol. Int. 19, 357-371, 1995.
7. 7. Shah, M., Foreman, D. M., and Ferguson, M. W. J., Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 108, 985-1002, 1995.
8. 8. Robson, M. C., Phillip, L. G., Cooper, D. M., Lyle, W. G., Robson, L. E., Odom, L., Hill, D. P., Hanham, A. F., and Ksander, G. A., Safety and effect of transforming growth factor-β2 for treatment of venous stasis ulcers. Wound Repair Regen. 3, 157-167, 1995.
9. 9. Beck, L. S., DeGuzman, L., Lee, W. P., Xu, Y., Siegel, M. W., and Amento, E. P., One systemic administration of transforming growth factor-β1 reverses age-or glucocorticoid-impaired wound healing. J. Clin. Invest. 92, 2841-2849, 1993.
10. 10. Sonis, S. T., Lindquist, L., Van Vugt, A., Stewart, A.A., Stam, K., Qu, G. Y., Iwata, K. K., and Haley, J. D., Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β3. Cancer Res. 54, 1135-1138, 1994.
11. 11. Sonis, S. T., and Haley, J. D., Pharmacological attenuation of chemotherapy-induced oral mucositis. Exp. Opin. Invest. Drugs 5, 1155-1162, 1996.
12. 12. Lemoli, R. M., Strife, A., Clarkson, B. D., Haley, J. D., and Gulati, S. C., TGF-Beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro. Exp. Hematol. 20, 1252-1256, 1992.
13. 13. Molineux, G., Migdalska, A., Haley, J., Evans, G. S., and Dexter, T. M., Total marrow failure induced by pegylated stem-cell factor administered before 5-fluorouracil. Blood 83, 3491-3499, 1994.
14. 14. Arnold, F., Cherry, G., Cox, D., Hutchinson, G., and Weston-Davies, W., Wound pharmacology: A report from the wound pharmacology forum. Wound Repair and Regeneration 4, 121-126, 1996.
15. 15. Stromberg, K., Chapekar, M. S., Goldman, B. A., Chambers, W. A., and Cavagnaro, J. A., Regulatory concerns in the development of topical recombinant ophthalmic and cutaneous wound healing biologies. Wound Repair Regen. 2, 155-164, 1994.
16. 16. Weiss, K. D., Siegel, J. P., and Gerrard, T. L., Regulatory issues in clinical applications of cytokines and growth factors. Prog. Growth Factor Res. 5, 231-222, 1994.
17. 17. Weissinger, J., Nonclinical regulatory considerations for wound-healing growth factors. Drug Dev. Res. 19, 275-283, 1990.
18. 18. Zioncheck, T. F., Chen, S. A., Richardson, L., Mora-Worms, M., Lucas, C., Lewis, D., Green, J. D., and Mordenti, J., Pharmacokinetic and tissue distribution of recombinant growth factor beta-1 after topical and intravenous administration in male rats. Pharmaceut. Res. 11, 213-220, 1994.
19. 19. Coffrey, R. J., Russell, W. E., and Barnard, J. A., Pharmacokinetic of TGF-β with emphasis on effects in liver and gut. Ann. N.Y. Acad. Sci. 593, 285-291, 1990.
20. 20. Wakefield, L. M., Winokur, T. S., Hollands, R. S., Christopherson, K., Levinson, A. D., and Sporn, M. B., Recombinant latent transforming growth factor-β1 has a longer plasma half-life in rats than active transforming growth factor-β1, and a different tissue distribution. J. Clin. Invest. 86, 1976-1984, 1990.
21. 21. Fontana, A., Constam, D. B., Frei, K., Malipiero, U., and Pfister, H. W., Modulation of the immune system by transforming growth factor-β. Int. Arch. Allergy Immunol. 99, 1-7, 1992.
22. 22. Adams, S., Pharmacology and toxicology of transforming growth factor beta. In "TGF-βs: Biological Mechanisms and Clinical Applications," p. 28, Fogarty International Centre Conference, NIH, Bethesda, MD, May 4-6, 1994. [Abstract]
23. 23. Border, W. A., and Noble, N. N., Transforming growth factor-β in tissue fibrosis. N. Engl. J. Med. 331, 1286-1292, 1994.
24. 24. Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B., and Ruoslahti, E., Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346, 371-373, 1990.
25. 25. Carlino, J. A., Higley, H. R., Avis, P. D., Chu, S. S., Ogawa, Y., and Ellingsworth, L. R., Hematologic and hematopoietic changes induces by systemic administration of TGF-β1. Ann. N.Y. Acad. Sci. 593, 330-333, 1990.
26. 26. Fausto, N., Mead, J. E., Gruppuso, P. A., Castilla, A., and Jakowlew, S. B., Effects of TGF-βs in the liver: Cell proliferation and fibrogenesis. In "Ciba Foundation Symposium 157, Clinical Applications of TGF-β," pp. 165-174, 1991.
27. 27. Ohno, K., Ammann, P., Fasciati, R., and Maier, P., Transforming growth factor-β1 preferentially induces apoptotic cell death in rat hepatocytes cultured under pericentral-equivalent conditions. Toxicol. Appl. Pharmacol. 132, 227-236, 1995.
28. 28. Terrell, T. G., Working, P. K., Chow, C. P., and Green, J. D., Pathology of recombinant human transforming growth factor-β1 in rats and rabbits. Int. Rev. Exp. Pathol. 34B, 43-67, 1993.
29. 29. Isaka, Y., Fujiwara, Y., Ueda, N., Kaneda, Y., Kamada, T., and Imai, E., Glomerusclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into rat kidney. J. Clin. Invest. 92, 2597-2601, 1993.
30. 30. Border, W. A., Transforming growth factor-β and the pathogenesis of glomerular diseases. Curr. Opin. Nephrol. Hypertens. 3, 54-59, 1994.
31. 31. Pratt, B. M., Vaccaro, C., Johnson, J., Callegari, S., and McPherson, J. M., Effects of high doses of transforming growth factor beta-2 (TGF-β2) on the murine adrenal gland. Wound Rep. Regen. 4, A170, 1996. [Abstract]
32. 32. Glick, A. B., Kulkarni, A. B., Tennenbaum, T., Hennings, H., Flanders, K. C., O'Reilly, M., Sporn, M. B., Karlsson, S., and Yuspa, S. H., Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc. Natl. Acad. Sci. USA 90, 6076-6080, 1993.
33. 33. Glick, A. B., Lee, M. M., Darwiche, N., Kulkarni, A. B., Karlsson, S., and Yuspa, S. H., Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev. 8, 2429-2440, 1994.
34. 34. Markowitz, S. D., and Roberts, A. B., Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev. 7, 93-102, 1996.